

# NUC-3373 Induced DAMPs release in CRC cells promotes natural killer cell activation

Oliver J. Read<sup>1,2</sup>, David J. Harrison<sup>1,2</sup>, Jennifer Bré<sup>1,2</sup>

1) NuCana, plc, Edinburgh, UK  
2) University of St Andrews, St Andrews UK

Abstract Number:  
1655

Email:  
ojr2@st-andrews.ac.uk



## BACKGROUND

- 5-fluorouracil (5-FU) is a key anti-cancer agent used across a broad range of tumors
- Fluorodeoxyuridine-monophosphate (FUDR-MP or FdUMP), the active anti-cancer metabolite of 5-FU, causes cell death via inhibition of thymidylate synthase (TS) preventing the conversion of dUMP to dTMP<sup>1</sup>
- Clinical efficacy of 5-FU is limited by
  - Short plasma half-life (8-14 minutes)<sup>1,2</sup> necessitating prolonged administration (46 hours)
  - Over 85% broken down by dihydropyrimidine dehydrogenase (DPD)<sup>3</sup>
  - Production of toxic catabolites such as FBAL (implicated in hand-foot syndrome)
  - Complex enzymatic activation, including thymidine phosphorylase (TP) and thymidine kinase (TK), conferring resistance

### NUC-3373: A targeted inhibitor of TS

- ProTide transformation of FUDR-MP, the active anti-cancer metabolite of 5-FU
- Designed to overcome the key 5-FU resistance mechanisms
  - Protected from breakdown by DPD
  - FUDR-MP generation independent of intracellular enzymatic activation
- NUC-3373 generates high levels of FUDR-MP compared to 5-FU in patient PBMCs (31  $\mu$ M vs 0.1  $\mu$ M)<sup>4</sup>
- Currently being investigated in clinical studies
  - NuTide:301 - Phase 1 dose-finding study in advanced solid tumors
  - NuTide:302 - Phase 1b combination study in advanced colorectal cancer (CRC)

### DAMPs and the immune microenvironment

- Interaction between cancer cells and immune cells in the microenvironment is key for determining patient prognosis and outcome
- Some chemotherapeutics have increased efficacy in immunocompetent over immunocompromised environments due to release of damage associated molecular patterns (DAMPs) from dying/injured cells<sup>5</sup>
- In addition to activation and maturation of dendritic cells, DAMPs can also activate NK cells, a key component of innate immunity<sup>6</sup>
- NUC-3373 induces ER stress and the release of immunogenic DAMPs from CRC cells<sup>7</sup>
  - CRT, ATP, and HMGB1
  - DAMP release occurred at a low dose of NUC-3373 (10  $\mu$ M)




Figure 1: NUC-3373 causes release of DAMPs from stressed cancer cells

**Aim**  
Investigate the effect of NUC-3373 on innate immunity utilizing a co-culture system

### Hypothesis


NUC-3373 induced DAMP release activates NK cells contributing to an anti-tumor immune response

## METHODS

### Characteristics of human CRC cell lines

	HCT116	HT29	SW480
Approximate doubling time (hr)	20	24	38
Basal TS expression	High	Low	Med
Microsatellite status	MSI	MSS	MSS
Concentration NUC-3373 ( $\mu$ M)	10	15	40

### CRC and NK cell co-culture system



- NK-92 MI cell line used as a model of NK cells<sup>8</sup>
- Positive control: PMA/ionomycin for NK activation
- DAMPs inducer: Oxaliplatin (10  $\mu$ M)
- For surface Hsp70 experiment there was no co-culture step
- Negative Control: DMSO (equivalent dilution) was used as a vehicle control for each cell line

## RESULTS

### NUC-3373 causes Hsp70 surface exposure on CRC cells indicative of a stress response






Figure 2: Proportion of CRC cells positive for surface Hsp70 expression

- NUC-3373 caused an increase in cells expressing Hsp70 on the plasma membrane
  - Hsp70 translocates to the cell membrane in stressed cancer cells
  - Hsp70 induces NK activation via interaction with Toll-like receptor 2 (TLR2)

### NUC-3373 increases NK activation resulting in degranulation and cytokine production




Figure 3: NK cell expression of LAMP1 and IFN- $\gamma$  following co-culture

- NUC-3373 causes increased surface LAMP1 expression indicating NK cells are being activated for cytotoxic activity
- After activation, NK cells upregulate cytokines such as IFN- $\gamma$  stimulating an anti-tumor response
  - NUC-3373 caused an increase in intracellular staining of IFN- $\gamma$
  - Response was most pronounced in HCT116 cells

### NUC-3373 reduces expression of immune checkpoint molecule TIGIT on NK cells




Figure 4: Surface expression of TIGIT on NK cells

### Markers

Marker	Description
Hsp70	Stress marker on CRC cells
CD56 (NCAM)	Distinguishes NK cells from CRC cells
LAMP1 (CD107a)	Degranulation marker indicating release of cytolytic vesicles from NK cells
IFN- $\gamma$	Indicates NK cell activation
TIGIT	Immunoinhibitory checkpoint molecule, causes NK cell exhaustion

- NUC-3373 and oxaliplatin cause a reduction in TIGIT expression on the surface of NK cells
- Reduction in TIGIT may be a consequence of DAMP release from stressed cancer cells
- NUC-3373 induced DAMPs may reduce NK cell exhaustion




Figure 5: NUC-3373 potentiates an innate anti-tumor immune response in NK cells through upregulation of degranulation and cytokine production and downregulation of inhibitory checkpoint TIGIT

## CONCLUSION

- NUC-3373 is a targeted TS inhibitor resulting in DNA damage and cancer cell death
- NUC-3373 also induces ER stress that promotes DAMP release
- NUC-3373 induced DAMPs activate a natural killer response
  - Increased degranulation and cytokine production
  - Output observed in CRC cell lines with different MSI/MSS and basal TS expression
- NUC-3373 induced DAMPs may restore NK cell-mediated immune responses by reducing inhibitory signals
- NUC-3373 has the potential to evoke immunogenic cell death and may enhance the clinical utility of immunotherapy agents